Fadrozole (CAS 102676-47-1) Suppliers and Product Information

Fadrozole is a selective, nonsteroidal aromatase inhibitor used in the treatment of breast cancer. It is classified as a second-generation aromatase inhibitor and has been sold under the brand name Afema by Novartis. Fadrozole works by inhibiting the enzyme aromatase, which is responsible for converting androgens to estrogens, thereby reducing estrogen levels in the body.

Frequently Asked Questions about Fadrozole

Q: What is the primary use of Fadrozole?

A: Fadrozole is primarily used as an antineoplastic agent for the treatment of estrogen-dependent diseases, particularly breast cancer.

Q: How does Fadrozole work?

A: Fadrozole is a selective aromatase inhibitor. It works by inhibiting the enzyme aromatase, which is responsible for the final step in estrogen biosynthesis. This action reduces estrogen levels in the body, which can slow or stop the growth of certain types of breast tumors that require estrogen to grow.

Q: What is the typical dosage of Fadrozole?

A: According to clinical data, Fadrozole has been used at dosages of 1 mg once daily or 2 mg twice daily orally, achieving 82.4% and 92.6% aromatase inhibition respectively in postmenopausal women.

Q: Is Fadrozole still in use?

A: While Fadrozole has been used in Japan for breast cancer treatment, it is considered a second-generation aromatase inhibitor. Third-generation inhibitors like anastrozole and letrozole are now more commonly used due to their higher potency and selectivity.